Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial

Additional Metadata
Persistent URL	doi.org/10.1016/S1470-2045(15)70025-2, hdl.handle.net/1765/91638
Journal	The Lancet Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Petrylak, D. P., Vogelzang, N. J., Budnik, N., Wiechno, P. J., Sternberg, C., Doner, K., Bellmunt, J., Burke, J. M., de Olza, M. O., Choudhury, A., Gschwend, J., Kopyltsov, E., Flechon, A., Van As, N., Houede, N., Barton, D., Fandi, A., Jungnelius, U., Li, S., … Fizazi, K. (2015). Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology.https://doi.org/10.1016/S1470-2045(15)70025-2

Publication